H. Lundbeck A/s

Allergan, Inc.

Acadia Pharmaceuticals Inc.

Ge Healthcare Limited

Jorgen Eskildsen

Anette Graven Sams

Ask Puschl

Kim Andersen

Roger Olsson

Garrick Paul Smith

Daniel Rodriguez Greve

Ask Püschl

Gitte Kobberoee Mikkelsen

Ethan S Burstein

Edward Robins

Alex Gibson

James Nairne

Anne Eeg Knapp

Veronique Morisson Iveson

Ethan Burstein

Joel Castillo

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine &#x3b1;7 receptor.

Positive allosteric modulators of nicotinic acetylcholine receptor

Compounds of formula (I) and methods are provided for the treatment of disease or conditions in which modification of cholinergic, especially muscarinic receptor activity, has a beneficial effect. 

Muscarinic agonists

The present invention relates to compounds of formula I wherein the substituents are as defined below. The compounds of formula I are useful for the treatment of diseases such as schizophrenia, including both the positive and the negative symptoms of schizophrenia and other psychoses. 

Aromatic oxyphenyl and aromatic sulfanylphenyl derivatives

Growing community of inventors

Copenhagen, Denmark

Jorgen Eskildsen